Freedom of Information request (FOI 22/1157)
Published 17 January 2024
FOI 22/1157
7th December 2022
Dear
Thank you for your email.
The change from CMA to MA was done following the second annual renewal of Comirnaty, where no new data emerged that would alter the benefit/risk for these products. The CHMP concluded that the clinical safety profile, as well as the efficacy of this product, may now be considered comprehensively characterised, in the sense of the conditional marketing authorisation (CMA) legislation and the CMA converted to a full MA.
Further information is available from the EMA, see the link below:
https://www.ema.europa.eu/en/medicines/human/EPAR/comirnaty
With regards to data submitted since January 2021 for Comirnaty, these are available through the EMA repository, linked below:
https://clinicaldata.ema.europa.eu/web/cdp
If you have a query about the information provided, please reply to this email.
If you disagree with how we have interpreted the Freedom of Information Act 2000 in answering your request, you can ask for an internal review. Please reply to this email, within two months of this reply, specifying that you would like an Internal Review to be carried out.
Please remember to quote the reference number above in any future communications.
If you were to remain dissatisfied with the outcome of the internal review, you would have the right to apply directly to the Information Commissioner for a decision. Please bear in mind that the Information Commissioner will not normally review our handling of your request unless you have first contacted us to conduct an internal review. The Information Commissioner can be contacted at:
Information Commissioner’s Office
Wycliffe House
Water Lane
Wilmslow
Cheshire
SK9 5AF
Yours sincerely
MHRA Customer Experience Centre